Defining the critical hurdles in cancer immunotherapy
详细信息 查看全文
- 作者：Bernard A Fox (1) (2)
Dolores J Schendel (3)
Lisa H Butterfield (4) (5) (6)
Steinar Aamdal (7)
James P Allison (8) (9)
Paolo Antonio Ascierto (10)
Michael B Atkins (11) (12)
Jirina Bartunkova (13)
Lothar Bergmann (14)
Neil Berinstein (15)
Cristina C Bonorino (16)
Ernest Borden (17) (18)
Jonathan L Bramson (19)
Cedrik M Britten (20) (21)
Xuetao Cao (22) (23)
William E Carson (24)
Alfred E Chang (25)
Dainius Characiejus (26)
A Raja Choudhury (27)
George Coukos (28)
Tanja de Gruijl (29)
Robert O Dillman (30)
Harry Dolstra (31)
Glenn Dranoff (32) (33) (34)
Lindy G Durrant (35)
James H Finke (36)
Jerome Galon (37)
Jared A Gollob (38)
Cécile Gouttefangeas (39)
Fabio Grizzi (40)
Michele Guida (41)
Leif H?kansson (42) (43)
Kristen Hege (117) (44)
Ronald B Herberman (45)
F Stephen Hodi (46) (47)
Axel Hoos (48)
Christoph Huber (49)
Patrick Hwu (50)
Kohzoh Imai (51)
Elizabeth M Jaffee (52)
Sylvia Janetzki (53)
Carl H June (54)
Pawel Kalinski (5)
Howard L Kaufman (55)
Koji Kawakami (56)
Yutaka Kawakami (57)
Ulrich Keilholtz (58)
Samir N Khleif (59)
Rolf Kiessling (60)
Beatrix Kotlan (61)
Guido Kroemer (62)
Rejean Lapointe (63) (64)
Hyam I Levitsky (65)
Michael T Lotze (4) (5) (6)
Cristina Maccalli (66)
Michele Maio (67)
Jens-Peter Marschner (68)
Michael J Mastrangelo (69)
Giuseppe Masucci (70)
Ignacio Melero (71)
Cornelius Melief (72)
William J Murphy (73)
Brad Nelson (74)
Andrea Nicolini (75)
Michael I Nishimura (76)
Kunle Odunsi (77)
Pamela S Ohashi (78)
Jill O’Donnell-Tormey (79)
Lloyd J Old (80)
Christian Ottensmeier (81)
Michael Papamichail (82)
Giorgio Parmiani (83)
Graham Pawelec (84)
Enrico Proietti (85)
Shukui Qin (86)
Robert Rees (87)
Antoni Ribas (88)
Ruggero Ridolfi (89)
Gerd Ritter (8) (80)
Licia Rivoltini (90)
Pedro J Romero (91)
Mohamed L Salem (92)
Rik J Scheper (93)
Barbara Seliger (94)
Padmanee Sharma (95)
Hiroshi Shiku (96) (97)
Harpreet Singh-Jasuja (98)
Wenru Song (99)
Per Thor Straten (100)
Hideaki Tahara (101)
Zhigang Tian (102) (103)
Sjoerd H van Der Burg (104)
Paul von Hoegen (105)
Ena Wang (106) (107)
Marij JP Welters (108)
Hauke Winter (109)
Tara Withington (110)
Jedd D Wolchok (8)
Weihua Xiao (111)
Laurence Zitvogel (112)
Heinz Zwierzina (113)
Francesco M Marincola (106) (107)
Thomas F Gajewski (114)
Jon M Wigginton (115)
Mary L Disis (116) - 刊名：Journal of Translational Medicine
- 出版年：2011
- 出版时间：December 2011
- 年：2011
- 卷：9
- 期：1
- 全文大小：376KB
- 参考文献：1. Ferlay J, Shin HR, Bray F, / et al.: plus-plus">Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. [p://globocan.iarc.fr" class="a-plus-plus">http://globocan.iarc.fr] / International Agency for Research on Cancer 2010. 2010
2. Milken M: plus-plus">Health-Care Investment - The Hidden Crisis. / The Wall Street Journal 2011.
3. Dillman RO, Fogel GB, Cornforth AN, / et al.: plus-plus">Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines. / Cancer biotherapy & radiopharmaceuticals 2011, plus-plus">26:407-5. p://dx.doi.org/10.1089/cbr.2011.0973">CrossRef
4. Mlecnik B, Tosolini M, Kirilovsky A, / et al.: plus-plus">Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. / Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011, plus-plus">29:610-. p://dx.doi.org/10.1200/JCO.2010.30.5425">CrossRef
5. Broussard EK, Disis ML: plus-plus">TNM staging in colorectal cancer: T is for T cell and M is for memory. / Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011, plus-plus">29:601-. p://dx.doi.org/10.1200/JCO.2010.32.9078">CrossRef
6. O'Donnell PH, Dolan ME: plus-plus">Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. / Clin Cancer Res 2009, plus-plus">15:4806-4. p://dx.doi.org/10.1158/1078-0432.CCR-09-0344">CrossRef
7. Baiocchi M, Biffoni M, Ricci-Vitiani L, / et al.: plus-plus">New models for cancer research: human cancer stem cell xenografts. / Curr Opin Pharmacol 2010, plus-plus">10:380-. p://dx.doi.org/10.1016/j.coph.2010.05.002">CrossRef
8. Bankert RB, Hess SD, Egilmez NK: plus-plus">SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. / Front Biosci 2002, plus-plus">7:c44-2. p://dx.doi.org/10.2741/bankert">CrossRef
9. Ishikawa F, Yasukawa M, Lyons B, / et al.: plus-plus">Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. / Blood 2005, plus-plus">106:1565-3. p://dx.doi.org/10.1182/blood-2005-02-0516">CrossRef
10. Stauffer JK, Scarzello AJ, Andersen JB, / et al.: plus-plus">Coactivation of AKT and beta-catenin in mice rapidly induces formation of lipogenic liver tumors. / Cancer research 2011, plus-plus">71:2718-7. p://dx.doi.org/10.1158/0008-5472.CAN-10-2705">CrossRef
11. Romer PS, Berr S, Avota E, / et al.: plus-plus">Preculture of PBMC at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. / Blood 2011, in press.
12. Morgan RA, Yang JC, Kitano M, / et al.: plus-plus">Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. / Molecular therapy : the journal of the American Society of Gene Therapy 2010, plus-plus">18:843-1. p://dx.doi.org/10.1038/mt.2010.24">CrossRef
13. Brentjens R, Yeh R, Bernal Y, / et al.: plus-plus">Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. / Molecular therapy : the journal of the American Society of Gene Therapy 2010, plus-plus">18:666-. p://dx.doi.org/10.1038/mt.2010.31">CrossRef
14. Butterfield LH, Disis ML, Fox BA, / et al.: plus-plus">A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". / J Transl Med 2008, plus-plus">6:81. p://dx.doi.org/10.1186/1479-5876-6-81">CrossRef
15. Visvader JE: plus-plus">Cells of origin in cancer. / Nature plus-plus">469:314-2.
16. Damia G, D'Incalci M: plus-plus">Genetic instability influences drug response in cancer cells. / Curr Drug Targets plus-plus">11:1317-4.
17. Fisher DE, Barnhill R, Hodi FS, / et al.: plus-plus">Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. / Pigment Cell Melanoma Res 2010, plus-plus">23:14-6. p://dx.doi.org/10.1111/j.1755-148X.2009.00655.x">CrossRef
18. Ko JM, Fisher DE: plus-plus">A new era: melanoma genetics and therapeutics. / J Pathol 2011, plus-plus">223:241-0. p://dx.doi.org/10.1002/path.2804">CrossRef
19. Finak G, Bertos N, Pepin F, / et al.: plus-plus">Stromal gene expression predicts clinical outcome in breast cancer. / Nat Med 2008, plus-plus">14:518-7. p://dx.doi.org/10.1038/nm1764">CrossRef
20. Butterfield LH, Palucka AK, Britten CM, / et al.: plus-plus">Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. / Clinical cancer research : an official journal of the American Association for Cancer Research 2011, plus-plus">17:3064-076. p://dx.doi.org/10.1158/1078-0432.CCR-10-2234">CrossRef
21. Gajewski TF, Louahed J, Brichard VG: plus-plus">Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. / Cancer J plus-plus">16:399-03.
22. Liakou CI, Kamat A, Tang DN, / et al.: plus-plus">CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. / Proceedings of the National Academy of Sciences of the United States of America 2008, plus-plus">105:14987-2. p://dx.doi.org/10.1073/pnas.0806075105">CrossRef
23. Carthon BC, Wolchok JD, Yuan J, / et al.: plus-plus">Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. / Clinical cancer research : an official journal of the American Association for Cancer Research 2010, plus-plus">16:2861-1. p://dx.doi.org/10.1158/1078-0432.CCR-10-0569">CrossRef
24. Sharma P, Wagner K, Wolchok JD, / et al.: plus-plus">Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. / Nature reviews Cancer 2011, plus-plus">11:805-2. p://dx.doi.org/10.1038/nrc3153">CrossRef
25. Koebel CM, Vermi W, Swann JB, / et al.: plus-plus">Adaptive immunity maintains occult cancer in an equilibrium state. / Nature 2007, plus-plus">450:903-. p://dx.doi.org/10.1038/nature06309">CrossRef
26. Ferrone C, Dranoff G: plus-plus">Dual roles for immunity in gastrointestinal cancers. / J Clin Oncol plus-plus">28:4045-1.
27. Schreiber TH, Podack ER: plus-plus">A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas. / Br J Cancer 2009, plus-plus">101:381-. p://dx.doi.org/10.1038/sj.bjc.6605198">CrossRef
28. Lake RA, Robinson BW: plus-plus">Immunotherapy and chemotherapy--a practical partnership. / Nat Rev Cancer 2005, plus-plus">5:397-05. p://dx.doi.org/10.1038/nrc1613">CrossRef
29. Zitvogel L, Apetoh L, Ghiringhelli F, / et al.: plus-plus">The anticancer immune response: indispensable for therapeutic success? / J Clin Invest 2008, plus-plus">118:1991-001. p://dx.doi.org/10.1172/JCI35180">CrossRef
30. Demaria S, Formenti SC: plus-plus">Sensors of ionizing radiation effects on the immunological microenvironment of cancer. / International journal of radiation biology 2007, plus-plus">83:819-5. p://dx.doi.org/10.1080/09553000701481816">CrossRef
31. Zitvogel L, Kepp O, Kroemer G: plus-plus">Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature reviews. / Clinical oncology 2011, plus-plus">8:151-0.
32. Begley J, Ribas A: plus-plus">Targeted therapies to improve tumor immunotherapy. / Clinical cancer research : an official journal of the American Association for Cancer Research 2008, plus-plus">14:4385-1. p://dx.doi.org/10.1158/1078-0432.CCR-07-4804">CrossRef
33. Harzstark AL, Small EJ: plus-plus">Immunotherapeutics in development for prostate cancer. / Oncologist 2009, plus-plus">14:391-. p://dx.doi.org/10.1634/theoncologist.2008-0240">CrossRef
34. Phan GQ, Yang JC, Sherry RM, / et al.: plus-plus">Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. / Proc Natl Acad Sci USA 2003, plus-plus">100:8372-. p://dx.doi.org/10.1073/pnas.1533209100">CrossRef
35. Hodi FS, Butler M, Oble DA, / et al.: plus-plus">Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. / Proc Natl Acad Sci USA 2008, plus-plus">105:3005-0. p://dx.doi.org/10.1073/pnas.0712237105">CrossRef
36. Cheever MA: plus-plus">Twelve immunotherapy drugs that could cure cancers. / Immunol Rev 2008, plus-plus">222:357-8. p://dx.doi.org/10.1111/j.1600-065X.2008.00604.x">CrossRef
37. Cheever MA, Schlom J, Weiner LM, / et al.: plus-plus">Translational Research Working Group developmental pathway for immune response modifiers. / Clin Cancer Res 2008, plus-plus">14:5692-. p://dx.doi.org/10.1158/1078-0432.CCR-08-1266">CrossRef
38. Cheever MA, Allison JP, Ferris AS, / et al.: plus-plus">The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. / Clin Cancer Res 2009, plus-plus">15:5323-7. p://dx.doi.org/10.1158/1078-0432.CCR-09-0737">CrossRef
39. Korman AJ, Melero I, Okada H, / et al.: plus-plus">Workshop on Immunotherapy Combinations. 2011.
40. Lonchay C, van der Bruggen P, Connerotte T, / et al.: plus-plus">Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. / Proceedings of the National Academy of Sciences of the United States of America 2004, plus-plus">101 Suppl 2:14631-. p://dx.doi.org/10.1073/pnas.0405743101">CrossRef
41. Lurquin C, Lethe B, De Plaen E, / et al.: plus-plus">Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. / The Journal of experimental medicine 2005, plus-plus">201:249-7. p://dx.doi.org/10.1084/jem.20041378">CrossRef
42. Britten CM, Gouttefangeas C, Welters MJ, / et al.: plus-plus">The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. / Cancer immunology, immunotherapy : CII 2008, plus-plus">57:289-02. p://dx.doi.org/10.1007/s00262-007-0378-0">CrossRef
43. Britten CM, Janetzki S, Ben-Porat L, / et al.: plus-plus">Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. / Cancer Immunol Immunother 2009, plus-plus">58:1701-3. p://dx.doi.org/10.1007/s00262-009-0681-z">CrossRef
44. Hodi FS, O'Day SJ, McDermott DF, / et al.: plus-plus">Improved survival with ipilimumab in patients with metastatic melanoma. / The New England journal of medicine 2010, plus-plus">363:711-3. p://dx.doi.org/10.1056/NEJMoa1003466">CrossRef
45. Janetzki S, Britten CM: plus-plus">The impact of harmonization on ELISPOT assay performance. / Methods in molecular biology 2012, plus-plus">792:25-6. p://dx.doi.org/10.1007/978-1-61779-325-7_2">CrossRef
46. Rosenberg SA, Dudley ME: plus-plus">Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. / Proc Natl Acad Sci USA 2004,plus-plus">101(Suppl 2)plus-plus">:14639-5. p://dx.doi.org/10.1073/pnas.0405730101">CrossRef
47. Kirkwood JM, Lee S, Moschos SJ, / et al.: plus-plus">Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. / Clin Cancer Res 2009, plus-plus">15:1443-1. p://dx.doi.org/10.1158/1078-0432.CCR-08-1231">CrossRef
48. McShane LM, Altman DG, Sauerbrei W: plus-plus">Identification of clinically useful cancer prognostic factors: what are we missing? / J Natl Cancer Inst 2005, plus-plus">97:1023-. p://dx.doi.org/10.1093/jnci/dji193">CrossRef
49. Lee JA, Spidlen J, Boyce K, / et al.: plus-plus">MIFlowCyt: the minimum information about a Flow Cytometry Experiment. / Cytometry A 2008, plus-plus">73:926-0.
50. Mehrle A, Rosenfelder H, Weiman S: plus-plus">MIACA - Minimum Information About a Cellular Assay. 2009.
51. Janetzki S, Britten CM, Kalos M, / et al.: plus-plus">"MIATA"-minimal information about T cell assays. / Immunity 2009, plus-plus">31:527-. p://dx.doi.org/10.1016/j.immuni.2009.09.007">CrossRef
52. Hoos A, Parmiani G, Hege K, / et al.: plus-plus">A clinical development paradigm for cancer vaccines and related biologics. / J Immunother 2007, plus-plus">30:1-5. p://dx.doi.org/10.1097/01.cji.0000211341.88835.ae">CrossRef
53. Hales RK, Banchereau J, Ribas A, / et al.: plus-plus">Assessing oncologic benefit in clinical trials of immunotherapy agents. / Ann Oncol 2010, plus-plus">21:1944-1. p://dx.doi.org/10.1093/annonc/mdq048">CrossRef
54. Hoos A, Eggermont AM, Janetzki S, / et al.: plus-plus">Improved endpoints for cancer immunotherapy trials. / J Natl Cancer Inst 2010, plus-plus">102:1388-7. p://dx.doi.org/10.1093/jnci/djq310">CrossRef
55. Wolchok JD, Hoos A, O'Day S, / et al.: plus-plus">Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. / Clin Cancer Res 2009, plus-plus">15:7412-0. p://dx.doi.org/10.1158/1078-0432.CCR-09-1624">CrossRef
56. Finke LH, Wentworth K, Blumenstein B, / et al.: plus-plus">Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). / Vaccine 2007, plus-plus">25:B97-B109. (suppl 2). 25:B97-B109 (suppl 2). 2007 p://dx.doi.org/10.1016/j.vaccine.2007.06.067">CrossRef
57. Hoos A, Britten CM, Huber C, / et al.: plus-plus">A methodological framework to enhance the clinical success of cancer immunotherapy. / Nature biotechnology 2011, plus-plus">29:867-0. p://dx.doi.org/10.1038/nbt.2000">CrossRef
58. plus-plus">FDA: Draft Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines 2009.
59. Kantoff PW, Higano CS, Shore ND, / et al.: plus-plus">Sipuleucel-T immunotherapy for castration-resistant prostate cancer. / The New England journal of medicine 2010, plus-plus">363:411-2. p://dx.doi.org/10.1056/NEJMoa1001294">CrossRef
60. Yuan J, Adamow M, Ginsberg BA, / et al.: plus-plus">Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. / Proceedings of the National Academy of Sciences of the United States of America 2011, plus-plus">108:16723-. p://dx.doi.org/10.1073/pnas.1110814108">CrossRef
61. Carpenter S: plus-plus">Science careers. Carving a career in translational research. / Science 2007, plus-plus">317:966-. p://dx.doi.org/10.1126/science.317.5840.966">CrossRef
62. Disis ML, Slattery JT: plus-plus">The road we must take: multidisciplinary team science. / Sci Transl Med plus-plus">2:22cm9.
63. SITC: plus-plus">Leading Cancer Immunotherapy Scientists and Research Teams Honored at iSBTc 25th Annual Meeting. 2010. - 作者单位：Bernard A Fox (1) (2)
Dolores J Schendel (3)
Lisa H Butterfield (4) (5) (6)
Steinar Aamdal (7)
James P Allison (8) (9)
Paolo Antonio Ascierto (10)
Michael B Atkins (11) (12)
Jirina Bartunkova (13)
Lothar Bergmann (14)
Neil Berinstein (15)
Cristina C Bonorino (16)
Ernest Borden (17) (18)
Jonathan L Bramson (19)
Cedrik M Britten (20) (21)
Xuetao Cao (22) (23)
William E Carson (24)
Alfred E Chang (25)
Dainius Characiejus (26)
A Raja Choudhury (27)
George Coukos (28)
Tanja de Gruijl (29)
Robert O Dillman (30)
Harry Dolstra (31)
Glenn Dranoff (32) (33) (34)
Lindy G Durrant (35)
James H Finke (36)
Jerome Galon (37)
Jared A Gollob (38)
Cécile Gouttefangeas (39)
Fabio Grizzi (40)
Michele Guida (41)
Leif H?kansson (42) (43)
Kristen Hege (117) (44)
Ronald B Herberman (45)
F Stephen Hodi (46) (47)
Axel Hoos (48)
Christoph Huber (49)
Patrick Hwu (50)
Kohzoh Imai (51)
Elizabeth M Jaffee (52)
Sylvia Janetzki (53)
Carl H June (54)
Pawel Kalinski (5)
Howard L Kaufman (55)
Koji Kawakami (56)
Yutaka Kawakami (57)
Ulrich Keilholtz (58)
Samir N Khleif (59)
Rolf Kiessling (60)
Beatrix Kotlan (61)
Guido Kroemer (62)
Rejean Lapointe (63) (64)
Hyam I Levitsky (65)
Michael T Lotze (4) (5) (6)
Cristina Maccalli (66)
Michele Maio (67)
Jens-Peter Marschner (68)
Michael J Mastrangelo (69)
Giuseppe Masucci (70)
Ignacio Melero (71)
Cornelius Melief (72)
William J Murphy (73)
Brad Nelson (74)
Andrea Nicolini (75)
Michael I Nishimura (76)
Kunle Odunsi (77)
Pamela S Ohashi (78)
Jill O’Donnell-Tormey (79)
Lloyd J Old (80)
Christian Ottensmeier (81)
Michael Papamichail (82)
Giorgio Parmiani (83)
Graham Pawelec (84)
Enrico Proietti (85)
Shukui Qin (86)
Robert Rees (87)
Antoni Ribas (88)
Ruggero Ridolfi (89)
Gerd Ritter (8) (80)
Licia Rivoltini (90)
Pedro J Romero (91)
Mohamed L Salem (92)
Rik J Scheper (93)
Barbara Seliger (94)
Padmanee Sharma (95)
Hiroshi Shiku (96) (97)
Harpreet Singh-Jasuja (98)
Wenru Song (99)
Per Thor Straten (100)
Hideaki Tahara (101)
Zhigang Tian (102) (103)
Sjoerd H van Der Burg (104)
Paul von Hoegen (105)
Ena Wang (106) (107)
Marij JP Welters (108)
Hauke Winter (109)
Tara Withington (110)
Jedd D Wolchok (8)
Weihua Xiao (111)
Laurence Zitvogel (112)
Heinz Zwierzina (113)
Francesco M Marincola (106) (107)
Thomas F Gajewski (114)
Jon M Wigginton (115)
Mary L Disis (116)
1. Robert W. Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Earle A. Chiles Research Institute, Portland, OR, USA
2. Department of Molecular Microbiology and Immunology and Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
3. Helmholtz Centre Munich, German Research Center for Environmental Health, Institute of Molecular Immunology and Clinical Cooperation Group “Immune Monitoring- Munich, Germany
4. Departments of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
5. Department of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
6. Department of Immunology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
7. Department of Clinical Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
8. Memorial Sloan-Kettering Cancer Center, New York, NY, USA
9. Howard Hughes Medical Institute, New York, NY, USA
10. Medical Oncology and Innovative Therapy, Instituto Nazionale Tumori-Fondazione ‘G. Pascale- Naples, Italy
11. Beth Israel Deaconess Medical Center, Boston, MA, USA
12. Harvard Medical School, Boston, MA, USA
13. Institute of Immunology, FOCIS Center of Excellence, 2nd Medical School, Charles University, Prague, Czech Republic
14. Goethe Universit?t Frankfurt Am Main,Medizinische Klinik II, Frankfurt, Am Main, Germany
15. IRX Therapeutics, New York, NY, USA
16. Instituto Nacional para o Controle do Cancer, Instituto de Pesquisas Biomédicas, PUCRS Faculdade de Biociências, PUCRS, Porto Alegre RS, Brazil
17. Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA
18. Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH, USA
19. Department of Pathology, McMaster University, Hamilton, ON, Canada
20. III. Medical Department, University Medical Center Mainz, Mainz, Germany
21. Ribological GmbH, Mainz, Germany
22. Chinese Academy of Medical Sciences, Beijing, China
23. National Key Laboratory of Medical Immunology, Institute of Immunology, Second Military Medical University, Shanghai, China
24. Department of Surgery, Ohio State University, Columbus, OH, USA
25. Department of Surgery, University of Michigan Medical Center, Ann Arbor, MI, USA
26. Faculty of Medicine, Vilnius University, Vilnius, Lithuania
27. University of Queensland, Brisbane, Australia
28. Ovarian Cancer Research Center, University of Pennsylvania Medical Center, Philadelphia, A, USA
29. Department of Medical Oncology, VU Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
30. Hoag Institute for Research and Education, Hoag Cancer Institute, Newport Beach, CA, USA
31. Department of Laboratory Medicine, Nijmegen Centre for Molecular Life Sciences, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
32. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
33. Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
34. Harvard Medical School, Boston, MA, USA
35. Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK
36. Department of Immunology, Cleveland Clinic Foundation, Cleveland, OH, USA
37. INSERM U872, Cordeliers Research Center, Paris, France
38. Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA
39. Department of Immunology, Institute for Cell Biology, University of Tuebingen, Tuebingen, Germany
40. Istituto Clinico Humanitas, IRCCS, Milan, Italy
41. Oncology Department, Oncology Institute, Bari, Italy
42. University of Lund, Lund, Sweden
43. CanImGuide Therapeutics AB, Hoellviken, Sweden
117. Celgene Corporation, San Francisco, CA, USA
44. University of California, San Francisco, CA
45. Intrexon Corporation, Germantown, MD, USA
46. Department of Medicine, Harvard Medical School, Boston, MA, USA
47. Dana-Farber Cancer Institute, Boston, MA, USA
48. Bristol-Myers Squibb Company, Wallingford, Connecticut, USA
49. Translational Oncology and Immunology Centre TRON at the Mainz University Medical Center, Mainz, Germany
50. Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
51. The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
52. Department of Oncology, the Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
53. ZellNet Consulting, Inc., Fort Lee, NJ, USA
54. Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
55. Rush University Cancer Center, Rush University Medical Center, Chicago, IL, USA
56. School of Medicine and Public Health, Kyoto University, Kyoto, Japan
57. Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
58. Dept. of Hematology and Medical Oncology, Charité Comprehensive Cancer Center, Berlin, Germany
59. Cancer Vaccine Section, NCI, NIH, Bethesda, MD, USA
60. Department of Oncology - Pathology, Cancer Center Karolinska, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
61. Department of Molecular Immunology and Toxicology, Center of Surgical and Molecular Tumor pathology, National Institute of Oncology, Budapest, Hungary
62. INSERM, U848, Institut Gustave Roussy, Villejuif, France
63. Research Center, University Hospital, Université de Montréal (CRCHUM), Montréal, Québec, Canada
64. Institut du Cancer de, Montréal, Montréal, Québec, Canada
65. School of Medicine, Oncology Center, Johns Hopkins University, Baltimore, MD, USA
66. Department of Molecular Oncology, Foundation San Raffaele Scientific Institute, Milan, Italy
67. Medical Oncology and Immunotherapy, Department of Oncology, University, Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
68. Merck KGaA, Darmstadt, Germany
69. Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA
70. Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
71. Department of Immunology, CIMA, CUN and Medical School University of Navarra, Pamplona, Spain
72. Deptartment of Immunohematology and Blood Transfusion, Leiden University Medical Centre, Leiden, the Netherlands
73. University of California-Davis Medical Center, Sacramento, CA, USA
74. Deeley Research Centre, BC Cancer Agency, Victoria, BC, Canada
75. Department of Internal Medicine, University of Pisa, Santa Chiara Hospital, Pisa, Italy
76. Loyola University Medical Center, Cardinal Bernardin Cancer Center, Oncology Institute, Maywood, IL, USA
77. Department of Gynecologic Oncology, Tumor Immunology and Immunotherapy Program, Roswell Park Cancer Institute, Buffalo, NY, USA
78. Ontario Cancer Institute/University Health Network, Toronto, ON, Canada
79. Cancer Research Institute, New York, NY, USA
80. Ludwig Institute for Cancer Research, New York, NY, USA
81. Experimental Cancer Medicine Centre, University of Southampton Faculty of Medicine, Southampton, UK
82. Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
83. Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, San Raffaele Scientific Institute, Milan, Italy
84. Center for Medical Research, University of Tuebingen, Tuebingen, Germany
85. Istituto Superiore di Sanita- Rome, Italy
86. Chinese PLA Cancer Center, Nanjing, China
87. The John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK
88. Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA
89. Immunoterapia e Terapia Cellulare Somatica, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola (FC), Italy
90. Unit of Immunotherapy of Human Tumors, IRCCS Foundation, Istituto Nazionale Tumori, Milan, Italy
91. Division of Clinical Onco-Immunology, Ludwig Center for Cancer Research of the University of Lausanne, Epalinges, Switzerland
92. Immunology and Biotechnology Unit, Department of Zoology, Faculty of Science, Tanta University, Kragujevac, Egypt
93. Dept. of Pathology, VU University Medical Center, Amsterdam, The Netherlands
94. Institute of Medical Immunology, Halle, Germany
95. MD Anderson Cancer Center, Houston, TX, USA
96. Department of Cancer Vaccine, Mie University Graduate School of Medicine, Mie, Japan
97. Department of Immuno-gene Therapy, Mie University Graduate School of Medicine, Mie, Japan
98. Immatics Biotechnologies GmbH, Tübingen, Germany
99. Millennium: The Takeda Oncology Company, Cambridge, MA, USA
100. Center for Cancer Immune Therapy (CCIT), Department of Hematology, Herlev Hospital, Herlev, Denmark
101. Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
102. Institute of Immunology, School of Life Sciences, University of Science and Technology of China, Hefei, China
103. Institute of Immunopharmacology & Immunotherapy, School of Pharmaceutical Sciences, Shandong University, Jinan, China
104. Experimental Cancer Immunology and Therapy, Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands
105. Euraccine Consulting Group, Brussels, Belgium
106. Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD, USA
107. Center for Human Immunology (CHI), NIH, Bethesda, MD, USA
108. Experimental Cancer Immunology and Therapy, Department of Clinical Oncology (K1-P), Leiden University Medical Center, Leiden, The Netherlands
109. Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
110. Society for Immunotherapy of Cancer, Milwaukee, WI, USA
111. Institute of Immunology, School of Life Science, University of Science and Technology of China, Hefei, China
112. Institut Gustave Roussy, Center of Clinical Investigations CICBT507, Villejuif, France
113. Department Haematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
114. University of Chicago Medical Center, Chicago, IL, USA
115. Discovery Medicine-Oncology, Bristol-Myers Squibb Company, Princeton, New Jersey, USA
116. Tumor Vaccine Group, Center for Translational Medicine in Women’s Health, University of Washington, Seattle, WA, USA
文摘
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer.